Lenalidomide Grindeks (Lenalidomide)

The drug binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This triggers the degradation of transcription factors Ikaros and Aiolos, which suppresses malignant plasma‑cell growth, inhibits new blood‑vessel formation, and modulates cytokine release, resulting in antitumor and immune‑regulating effects.

The prescribed dose of Lenalidomide Grindeks is individualized by the treating physician based on the specific indication, disease stage, patient’s renal function, blood‑count parameters, and prior therapies. Only a qualified healthcare professional should set the dosing schedule.

Lenalidomide is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. Safety during breastfeeding has not been established, and nursing is generally discouraged.

To place an order, submit an enquiry on the Lenalidomide Grindeks product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, similar to thalidomide but with a more favorable safety profile and stronger anti‑angiogenic activity. Compared with thalidomide, lenalidomide generally causes fewer peripheral neuropathy events and offers greater efficacy in certain myelodysplastic syndromes, though both require careful monitoring for blood‑cell suppression and thrombotic risk.

Store Lenalidomide Grindeks at or below 25 °C (77 °F) in its original container, protected from moisture and direct light. Keep the product out of reach of children and avoid storing it in areas with high humidity or temperature fluctuations.

Lenalidomide Grindeks is taken orally, usually as a whole tablet or capsule, with or without food, according to the prescribing physician’s instructions. The exact timing and frequency are determined by the treating clinician based on the patient’s therapeutic plan.

Serious adverse events include severe neutropenia, thrombocytopenia, venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if signs of infection, unusual bleeding, or severe skin changes occur.

Lenalidomide Grindeks should be avoided in patients who are pregnant, have uncontrolled infections, or have a known hypersensitivity to lenalidomide or any of its excipients. Caution is also advised for individuals with severe renal impairment, active thrombotic disorders, or those receiving live vaccines.